BACKGROUND: We recently reported a more rapid waning of vaccine-induced humoral immunity (measles vaccine) in children with asthma. It is unknown if asthma affects susceptibility to vaccine-preventable diseases. OBJECTIVE: To determine whether asthma is associated with an increased risk of vaccine-preventable disease, e.g., breakthrough varicella infection. METHODS: This was a retrospective population-based case-control study that examined cases of breakthrough varicella among children between 2005 and 2011. Children with a diagnosis of breakthrough varicella infection in Olmsted County, Minnesota (infection of >42 days after vaccination) between 2005 and 2011 and two age- and sex-matched controls were enrolled for each case. Asthma status was determined by using predetermined criteria. Conditional logistic regression models were used to calculate matched odds ratios (OR) and their corresponding 95% confidence intervals (CI). RESULTS: Of the 165 cases and their 330 matched controls, 48% were boys and the mean (standard deviation) age at the index date was 6.6 ± 3.5 years for both cases and controls. Of the 330 controls, 80 (24%) had two doses of the varicella vaccine compared with only 23 (14%) of the 165 cases (OR 0.29 [95% CI, 0.14-0.61]; p = 0.001). Children with a history of asthma ever had a higher risk of developing breakthrough varicella compared with those without a history of asthma (adjusted OR 1.63 [95% CI, 1.04-2.55]; p = 0.032) when adjusting for elapsed time since the first varicella vaccination and the number of varicella vaccine doses. CONCLUSIONS: A history of asthma might be an unrecognized risk factor for breakthrough varicella infection. Children with asthma should follow the two-dose varicella vaccine policy.
BACKGROUND: We recently reported a more rapid waning of vaccine-induced humoral immunity (measles vaccine) in children with asthma. It is unknown if asthma affects susceptibility to vaccine-preventable diseases. OBJECTIVE: To determine whether asthma is associated with an increased risk of vaccine-preventable disease, e.g., breakthrough varicella infection. METHODS: This was a retrospective population-based case-control study that examined cases of breakthrough varicella among children between 2005 and 2011. Children with a diagnosis of breakthrough varicella infection in Olmsted County, Minnesota (infection of >42 days after vaccination) between 2005 and 2011 and two age- and sex-matched controls were enrolled for each case. Asthma status was determined by using predetermined criteria. Conditional logistic regression models were used to calculate matched odds ratios (OR) and their corresponding 95% confidence intervals (CI). RESULTS: Of the 165 cases and their 330 matched controls, 48% were boys and the mean (standard deviation) age at the index date was 6.6 ± 3.5 years for both cases and controls. Of the 330 controls, 80 (24%) had two doses of the varicella vaccine compared with only 23 (14%) of the 165 cases (OR 0.29 [95% CI, 0.14-0.61]; p = 0.001). Children with a history of asthma ever had a higher risk of developing breakthrough varicella compared with those without a history of asthma (adjusted OR 1.63 [95% CI, 1.04-2.55]; p = 0.032) when adjusting for elapsed time since the first varicella vaccination and the number of varicella vaccine doses. CONCLUSIONS: A history of asthma might be an unrecognized risk factor for breakthrough varicella infection. Children with asthma should follow the two-dose varicella vaccine policy.
Authors: Young J Juhn; Hirohito Kita; Linda A Lee; Rebecca J Swanson; Ryan Smith; Stephanie M Bagniewski; Amy L Weaver; V Shane Pankratz; Robert M Jacobson; Gregory A Poland Journal: Ann Allergy Asthma Immunol Date: 2006-10 Impact factor: 6.347
Authors: Maryam B Haddad; Mary B Hill; Andrew T Pavia; Caroline E Green; Aisha O Jumaan; Anindya K De; Robert T Rolfs Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: K Murphy; K Ververeli; B M Harvey; A L Duke; J Chapas-Crilly; T Uryniak; E Lyzell; W Mezzanotte Journal: Int J Clin Pract Date: 2006-12 Impact factor: 2.503
Authors: Bong-Seong Kim; Sonia Mehra; Barbara Yawn; Charles Grose; Robert Tarrell; Brian Lahr; Young J Juhn Journal: J Pediatr Date: 2013-04-13 Impact factor: 4.406
Authors: Nicola A Hanania; Marianna Sockrider; Mario Castro; Janet T Holbrook; James Tonascia; Robert Wise; Robert L Atmar Journal: J Allergy Clin Immunol Date: 2004-04 Impact factor: 10.793
Authors: Barbara Kuter; Holly Matthews; Henry Shinefield; Steve Black; Penelope Dennehy; Barbara Watson; Keith Reisinger; Lee Lian Kim; Lisa Lupinacci; Jonathan Hartzel; Ivan Chan Journal: Pediatr Infect Dis J Date: 2004-02 Impact factor: 2.129
Authors: Sandra S Chaves; Paul Gargiullo; John X Zhang; Rachel Civen; Dalya Guris; Laurene Mascola; Jane F Seward Journal: N Engl J Med Date: 2007-03-15 Impact factor: 91.245
Authors: Barbara Masten; Bennie McWilliams; Mary Lipscomb; Teressa Archibeque; Clifford Qualls; H William Kelly; Mark Schuyler Journal: Pediatr Pulmonol Date: 2003-12
Authors: Ji Hyen Hwang; Ki Hwan Kim; Seung Beom Han; Hyun Hee Kim; Jong-Hyun Kim; Soo Young Lee; Ui Yoon Choi; Jin Han Kang Journal: Clin Exp Vaccine Res Date: 2019-07-31
Authors: Anna Bednarek; Anna Bodajko-Grochowska; Robert Klepacz; Katarzyna Szczekala; Danuta Zarzycka; Andrzej Emeryk Journal: Postepy Dermatol Alergol Date: 2021-03-10 Impact factor: 1.837